UK markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
28.66-0.16 (-0.56%)
At close: 04:00PM EDT
28.79 +0.13 (+0.44%)
After hours: 05:14PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • T
    Tony
    What’s going on with this stock? I bought at $32 like a week ago and we sinking ever since
  • r
    rob s
    Can someone please explain why GSK maintains different research on Zantec than the FDA? GSK says they can prove it does not cause cancer, yet, FDA says it does and had it pulled. Which science is one to believe?
  • r
    rob s
    Unilever offered $50b for consumer business and the board shut it down? Woa! I guess they are not worried about law suits or future performance.
  • A
    Anonymous
    The status of two problems for GSK. Internal problem is lawsuit that has been baked into the stock price. The second is UK economic downturn that is being factored in the price. If GSK management gives a positive comment in the coming earning date, the stock is likely to rebound sharply.
  • e
    eduardo
    2017-2022 is enough time for GSK trend correction and it hasn't happened. Emma should leave, Everyone in this company is winning except investors.
  • L
    Loius
    GSK.L and BITCOIN on the rise🚀
  • F
    Felipe
    MASSIVE order are coming in at the close, huge volume. Large institutions on the move again🤑🚀
  • e
    eduardo
    GSK should fire the one/es responsible/s for the UL Haleon offer rejection. Right they should be ejected from GSK with no looking back. By the way, GSK's performance after the spin-off couldn't have gone worse.
  • M
    Michael
    My plan is to buy 50 - 100 shares every month.
    In H2 2023 GSK will recover.
    So time enough for me to load the boat with cheap shares.

    Have a nice weekend
  • e
    eduardo
    Research chief Mr. Barron left before the spin-off not after buying a handful of optional GSK shares granted to him at around 46 $ per ADR which he happily acquired as a nice friendly farewell gesture to Mrs. Walmsley's all-mighty governance over the company. Very odd indeed how things have turned out at the end of the so-called glorious spin-off of the decade for this Brit Company. No extra divid ,no gifted Haleon shares.No way, we practically paid with blood, sweat, and tears the Haleon shares with a 25% decrease of our GSK share count. My disappointment with the GSK top management is perhaps as big as Mr Paul Simon wonder where did he go or if he perhaps is able to explain how having reduced the outstanding share count by 20% (to finance the Haleon new shares distribution) and keep the valuation untouched the shares went down around 25% with no apparent reason after this glorious spin-off. Also, I would like to know why the 50B British pounds or 68B US dollars at the time of the offering for Haleon shares was happily rejected by GSK-MGM. Do they realize the disastrous GSK market valuation now? Do they really know anything at all about finance ? Please do not blame all on interest rate hikes. Very unhappy with your tenure Mrs. Walmsley -So far not so good. Excuse the typing and grammar errors.
  • S
    Simon
    buy now and be happy later. collect a huge dividend in the mean time
  • B
    Bobby
    $PRTK conversation
    Explain to me how $PRTK is not at least up 20% today on the news that $GSK is now a 25% shareholder in $SPRO and has given them $60mil to continue their pursuit of the phase 3 study in an oral only UTI drug. $PRTK has 2 approved drugs, 1 of which Nuzyra has 2 approved indications for oral only, and fast tracking on a 3rd orphan status disease with high cost of treatment (aka big dollars coming $PRTK way). Not to mention the potential for anthrax treatment and battlefield wound treatment in the coming global conflicts we are dead staring in the face.

    This stock is so manipulated due to the low volume, the big fish are keeping it suppressed until a 200%+ day comes, then a buyout shortly after. Stay long, stay strong
  • L
    Lusca
    Investment are stepping stone for success. waiting for the government to provide is a big waste
  • J
    Johan
    In 1992....GSK was at $29

    30 years later....same.

    So only the workers/managers who got good salaries and free shares were good.

    Wow!
  • P
    Prgnsft
    At this price this now becomes a reasonable take out at 40 by long list of major pharma
    The price action from mid 40s to below 30 is beyond reproach
    She has to go
  • M
    Mike
    if we have reached a bottom...along with SNY.....what is the recovery going to look like....will we be back in the 40s in a month? I would be happy with that
  • o
    ou71764
    Reversal day - GSK made a 52 week low intra-day but closed higher on the day. Not all reversal days mean that the bottom is in, but in this case, I think it does. GSK was very oversold. I added today. If the buying continues tomorrow, I'll add more.
  • r
    rob s
    I agree with Citigroup, the Zantec case will become a non-issue for a variety of reasons. Bought in today.
  • r
    rp.84332
    bought at $34 sold covered calls all the way down. selling covered calls helps lower base price while this bases thru Jan 23 and until tax loss sales are behind us.
  • J
    Johnfod
    Wait... REALLY!! Did GSK actually go up today?? Really????